Michael Mina

Michael Mina, a former Harvard epidemiologist and current chief scientific officer at eMed, reveals the surprising impact of measles on the immune system, leading to what's called 'immune amnesia.' He discusses how measles can weaken immune responses and increase vulnerability to other diseases. Stephen Russell, co-founder of Vyriad and a former Mayo Clinic researcher, shares innovative approaches using the measles virus to target cancer cells, exploring this exciting frontier of virotherapy and its potential benefits for cancer treatment.

Michael Mina, an immunologist and epidemiologist from Harvard, dives into the transformative role of rapid at-home COVID testing. He emphasizes their importance in managing public health and mitigating anxiety, contrasting them with traditional PCR tests. Mina critiques the slow governmental response to testing regulation and advocates for straightforward policies to increase accessibility. He also touches on the balance between privacy and health data, urging for clear communication to build public trust during these challenging times.

In a thought-provoking discussion, Dr. Michael Mina, an influential epidemiologist, and Dr. Rachael Bedard, a dedicated internist and health advocate, dive into the controversial ACIP decision to end the universal Hepatitis B birth dose. They challenge the implications this decision has on childhood vaccination and public trust in health systems. Exploring vaccine hesitancy, the importance of integrating sociology into public health, and lessons from COVID-19, they urge a shift from fear-based messaging to community engagement for better health outcomes.

Michael Mina, an esteemed immunologist and physician at Harvard, is renowned for his pioneering work on rapid COVID-19 testing. In this engaging conversation, he discusses the critical role of rapid testing in managing pandemics and its potential to empower individuals. Mina delves into the intricate relationship between viruses and society, the engineering approaches needed in public health, and how innovative technologies can enhance our understanding of viral behaviors. He also addresses the balance between data collection and personal privacy in tackling health crises.

Marc Elia, Invivyd board chair with finance and biotech experience, and Dr. Michael Mina, epidemiologist and immunologist who led Test-to-Treat, discuss monoclonal antibodies. They cover how monoclonals work across diseases, their roles as treatment versus prevention, using them alongside vaccines, prospects for measles and RSV therapeutics, cost and market challenges, and rebuilding public trust in medical choices.